RxSight (RXST) Cash from Operations Growth (1y) (2021 - 2026)
RxSight (RXST) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 122.43% |
| 10 | RxSight | 234.21 Mn | -184.00 Mn | 23.50 Mn | -23.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.31% |
| Dec 31, 2025 | 73.80% |
| Sep 30, 2025 | -282.62% |
| Jun 30, 2025 | -8.67% |
| Mar 31, 2025 | 5.12% |
| Dec 31, 2024 | 48.68% |
| Sep 30, 2024 | 108.14% |
| Jun 30, 2024 | 46.63% |
| Mar 31, 2024 | 47.60% |
| Dec 31, 2023 | 40.08% |
| Sep 30, 2023 | 47.45% |
| Jun 30, 2023 | 49.09% |
| Mar 31, 2023 | -18.55% |
| Dec 31, 2022 | -58.84% |
| Sep 30, 2022 | -10.42% |
| Jun 30, 2022 | -23.74% |
| Mar 31, 2022 | -46.17% |
| Dec 31, 2021 | -6.02% |
| Sep 30, 2021 | -97.97% |